Butyrate and Transplant Hearts: A Promising Cell Study

Butyrate may one day help protect donor hearts during transplantation. In a 2026 cell-culture study, researchers reported that adding the short-chain fatty acid to organ-preservation solution improved several measures of mitochondrial function in human adult ventricular cardiomyocytes exposed to simulated cold ischemia and reperfusion.

That is a serious and specific finding. It is also very far from evidence that a butyrate supplement, or a high-fiber meal, prevents heart attacks or repairs injured hearts. The experiment modeled a procedure-based use: adding butyrate directly to University of Wisconsin preservation solution while donor-heart cells undergo cold storage. It did not test oral delivery, patients, transplant outcomes, or survival.

A targeted experiment in ischemia-reperfusion injury

Ischemia-reperfusion injury occurs when blood supply returns after a period of oxygen deprivation. The restored oxygen is necessary, but the transition can trigger oxidative stress, mitochondrial failure, and cell death. It is a central problem in transplantation and also matters after myocardial infarction.

Ruidas et al., writing in Atherosclerosis in 2026, used human adult ventricular cardiomyocytes in a standardized cold ischemia-reperfusion model with University of Wisconsin solution. The cells received butyrate during cold ischemia, then underwent simulated reperfusion. This design makes the immediate clinical question unusually clear: could butyrate help preserve a donor heart before transplantation?

The study reported a coherent pattern across cellular endpoints. Butyrate restored the NAD⁺/NADPH redox balance disrupted by ischemia, reduced the ADP/ATP ratio, reduced mitochondrial reactive oxygen species, and restored electron-transport-chain activity. It also improved coupling between glycolysis and oxidative phosphorylation and reduced apoptosis compared with untreated ischemia-reperfusion controls.

The investigators also found evidence consistent with HDAC inhibition and PINK1/Parkin-mediated mitophagy. In practical terms, the proposed mechanism is that butyrate helped cells remove damaged mitochondria, replace them with functioning organelles, and recover energy production. A single favorable biomarker can mislead. Several measurements moving in the same direction make the cellular story more credible.

Still, these are surrogate outcomes in isolated cells. They do not establish that a preserved donor heart would pump better after transplant, that recipients would have fewer complications, or that any patient would live longer.

Why human heart cells matter

Many early cardiac studies use rodent cells or animal models. Human adult ventricular cardiomyocytes narrow one common translational gap because the experiment examines the relevant human cell type. The molecular pathways under study—redox control, mitochondrial quality control, energy metabolism, and apoptosis—also have direct relevance to cardiac injury.

The preservation-solution setting is another strength. University of Wisconsin solution is used for donor-organ preservation, so this was not a generic stress experiment in an arbitrary buffer. The model resembles a real clinical setting more closely than a claim that butyrate broadly "supports heart health."

But resemblance is not equivalence. Isolated cells cannot reproduce blood flow, immune activation, donor variability, tissue architecture, or the many decisions involved in transplant care. The study's abstract also does not report the butyrate concentration. Without that number, readers cannot judge whether the tested exposure is achievable in a preservation solution, much less after oral supplementation.

The gut-heart evidence is plausible, not proof

Butyrate is produced mainly when colonic microbes ferment dietary fiber. That fact has made it a favorite character in microbiome health stories, often cast as a tiny intestinal superhero with excellent public relations. The human cardiovascular evidence is more restrained.

In a 2021 HFpEF study by Beale et al., patients with heart failure with preserved ejection fraction had significantly lower abundance of short-chain-fatty-acid-producing microbial taxa than controls without significant medical history, independent of clinical confounders. The finding supports the idea that reduced microbial capacity to produce SCFAs may accompany HFpEF. Because the study was cross-sectional, it cannot show that lower SCFA-producing taxa caused heart failure.

That limitation applies to the wider literature. A 2023 systematic review by Simadibrata et al. found that heart failure patients consistently differ from healthy people in gut microbiota composition, but the direction of causation remains unresolved. Heart failure can alter intestinal blood flow, inflammation, motility, medication exposure, and diet. Each could change the microbiome after disease begins.

A 2024 fecal metaproteomics study by Yang et al. likewise found that gut microbial protein profiles could discriminate cardiovascular-risk patterns across healthy people and heart-failure patients. It shows that microbial functional output carries cardiovascular signal. It does not identify butyrate as the cause of that signal or establish that changing the microbiome improves cardiac outcomes.

Other findings support the existence of a gut-cardiovascular connection without supplying a butyrate mechanism. Khan et al. compared blood microbial populations in 29 myocardial infarction patients and 29 healthy controls and reported lower alpha diversity and different community structure in the myocardial infarction group. This case-control result concerns blood microbiome differences and possible microbial translocation; it does not show that butyrate reaches injured heart cells or restores their mitochondria.

Gut-derived does not mean heart-protective

The microbiome produces metabolites with opposing cardiovascular associations. Romano et al. linked the gut microbiota-generated metabolite phenylacetylglutamine, or PAGln, to worse cardiovascular outcomes in heart-failure patients and to atherothrombotic heart disease. PAGln is not butyrate, and this does not contradict the cell experiment directly. It does puncture a lazy inference: a molecule's microbial origin says nothing by itself about whether it benefits the heart.

That distinction matters because the butyrate experiment bypassed the gut entirely. The researchers placed butyrate directly in preservation solution with cardiomyocytes. Oral butyrate must survive intestinal handling and extensive first-pass metabolism before it could reach systemic circulation. Fiber can support microbial SCFA production, but no study described here shows that dietary fiber produces a cardiac butyrate concentration comparable to the experimental exposure.

What would move this from hypothesis to treatment?

The next evidence should match the question the experiment actually asks. Animal models of cardiac ischemia-reperfusion could test whether adding butyrate to preservation solution improves organ function after transplantation. Ex vivo donor-heart perfusion studies could measure cardiac performance under conditions closer to clinical practice. Pharmacokinetic work would need to establish appropriate concentrations in University of Wisconsin or histidine-tryptophan-ketoglutarate preservation media.

Only then would human transplant studies make sense. A separate research path would be needed for oral butyrate, fiber, or other microbiome interventions after myocardial infarction. Those approaches have different dosing, delivery, biology, and endpoints. They cannot borrow clinical credibility from an ex vivo preservation experiment.

Verdict: Butyrate has a credible cellular case as an additive to donor-heart preservation solution. It does not yet have a clinical case as a cardiac supplement or dietary therapy.

The most interesting feature of this work is its restraint. It points toward a testable transplant-medicine application rather than promising that the microbiome has solved cardiovascular disease. Until animal, pharmacokinetic, and human outcome data arrive, that narrow claim is the one the evidence can carry.